Merrimack Pharmaceuticals, Inc. (MACK) Set to Announce Quarterly Earnings on Tuesday
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) will be issuing its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
Merrimack Pharmaceuticals (NASDAQ:MACK) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.37) by ($0.81). During the same quarter in the prior year, the business posted ($4.00) earnings per share. On average, analysts expect Merrimack Pharmaceuticals to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.
Shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) opened at $11.71 on Monday. The company has a current ratio of 2.45, a quick ratio of 2.45 and a debt-to-equity ratio of 0.46. Merrimack Pharmaceuticals, Inc. has a 12 month low of $11.14 and a 12 month high of $67.90.
MACK has been the subject of several research reports. ValuEngine upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Zacks Investment Research downgraded Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Robert W. Baird reiterated a “hold” rating and set a $15.00 price target on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $64.53.
In other Merrimack Pharmaceuticals news, Director Ulrik B. Nielsen sold 21,556 shares of Merrimack Pharmaceuticals stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $14.40, for a total transaction of $310,406.40. Following the completion of the transaction, the director now owns 37,437 shares in the company, valued at approximately $539,092.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ulrik B. Nielsen sold 7,896 shares of Merrimack Pharmaceuticals stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $14.23, for a total value of $112,360.08. Following the transaction, the director now owns 22,781 shares of the company’s stock, valued at approximately $324,173.63. The disclosure for this sale can be found here. Insiders have sold a total of 44,308 shares of company stock valued at $637,558 in the last quarter. Company insiders own 8.53% of the company’s stock.
An institutional investor recently raised its position in Merrimack Pharmaceuticals stock. The Manufacturers Life Insurance Company raised its stake in shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) by 14.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 113,235 shares of the biopharmaceutical company’s stock after purchasing an additional 14,591 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.09% of Merrimack Pharmaceuticals worth $141,000 as of its most recent SEC filing.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.